Doxycycline as a cardioprotective agent in ST-elevation myocardial infarction: a pilot study addressing pre- reperfusion administratio

Phase 4

Completed

• Conditions: Myocardial Infarction; ST-Elevation Myocardial Infarction (STEMI); Cardiovascular - Coronary heart disease; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12618000467235
• Lead Sponsor: Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-29
• Study Completion: 2021-04-01
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 103

Inclusion Criteria

Consecutive men aged greater than 18 years and women aged greater than 55, or women less than 55 years and have no possibility of being pregnant; and
- Presenting within 12 hours of the onset of chest pain and with ECG findings of anterior or inferior ST-segment elevation or new left bundle branch block and for whom the clinical decision has been made to treat with PPCI; and
- Occlusion of the culprit related artery (TIMI grade 0 or TIMI grade 1) on coronary angiography, proximal and/or mid left anterior descending artery (LAD), or proximal dominant left circumflex (LCx) or dominant right coronary artery (RCA)

Exclusion Criteria

•Historical or Electrocardiograph (ECG) evidence of previous myocardial infarction; or
•Patients with prior coronary artery bypass grafting (CABG); or
•Previous revascularisation procedure where this procedure (PCI) was performed in the LAD/RCA; or
•Known pre-existing left ventricular dysfunction; or
•Known or suspected pregnancy; or
•Patients presenting with cardiac arrest or cardiogenic shock; or
•Patients undergoing rescue PCI for failed thrombolysis; or
•Patients with left main coronary artery stenosis of such severity that after PCI of their culprit lesion (LAD/RCA) they are likely to require coronary artery bypass graft (CABG) within the time course of the study period (6 months).
•Known allergy to tetracyclines;
•Contraindications to CMR

Study & Design

• Study Type: Interventional
• Study Design: Not specified